CoChat
Sign Up
Cited by 122Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNanoparticle-Based Drug Delivery

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges

Open access
Cano, Amanda, Turowski, Patric, Ettcheto, Miren, Duskey, Jason Thomas, Tosi, Giovanni, Sánchez-López, Elena, García, Maria Luisa, Camins, Antonio +4 more·2021·Journal of Nanobiotechnology
DOI 10.1186/s12951-021-00864-xPMC PMC8086346
Open this paper in CoChat — free accountOpen PDF

Abstract

Increasing life expectancy has led to an aging population, which has consequently increased the prevalence of dementia. Alzheimer's disease (AD), the most common form of dementia worldwide, is estimated to make up 50–80% of all cases. AD cases are expected to reach 131 million by 2050, and this increasing prevalence will critically burden economies and health systems in the next decades. There is currently no treatment that can stop or reverse disease progression. In addition, the late diagnosis of AD constitutes a major obstacle to effective disease management. Therefore, improved diagnostic tools and new treatments for AD are urgently needed. In this review, we investigate and describe both well-established and recently discovered AD biomarkers that could potentially be used to detect AD at early stages and allow the monitoring of disease progression. Proteins such as NfL, MMPs, p-tau217, YKL-40, SNAP-25, VCAM-1, and Ng / BACE are some of the most promising biomarkers because of their successful use as diagnostic tools. In addition, we explore the most recent molecular strategies for an AD therapeutic approach and nanomedicine-based technologies, used to both target drugs to the brain and serve as devices for tracking disease progression diagnostic biomarkers. State-of-the-art nanoparticles, such as polymeric, lipid, and metal-based, are being widely investigated for their potential to improve the effectiveness of both conventional drugs and novel compounds for treating AD. The most recent studies on these nanodevices are deeply explained and discussed in this review. Graphic Abstract

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12951-021-00864-x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Nanoparticles with sizes between 10 and 1000 nm, capable of encapsulating therapeutic molecules by targeting transport processes in the central nervous system, can improve the crossing of molecules through the blood-brain barrier in neurological disorders and reach targeted brain regions.

    “The use of nanoparticles (NP), with sizes between 10 and 1000 nm, capable of encapsulating therapeutic molecules by targeting transport processes in the CNS, can improve the crossing of molecules through the BBB in neurological disorders and reach targeted brain regions [29,30,31].”

    From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [31]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 183

  1. [3]Cummings JL Isaacson RS Schmitt FA Velting DM A practical algorithm for managing Alzheimer’ s disease: what, when, and why ? Ann Clin Transl Neurol 2015 2 3 307 323 10.1002/acn3.166 25815358 PMC4369281 · DOI
  2. [4]Anand R Dip K Ali A Therapeutics of Alzheimer’ s disease: past, present and future Neuropharmacology 2014 76 27 50 10.1016/j.neuropharm.2013.07.004 23891641 · DOI
  3. [5]Mendez MF Program BN Greater VA Angeles L Early-onset Alzheimer’s disease Neurol Clin 2017 35 2 263 281 10.1016/j.ncl.2017.01.005 28410659 PMC5407192 · DOI
  4. [6]Hang T Seelaar H Melhem S Rozemuller AJM Van Swieten JC Genetic screening in early-onset Alzheimer’ s disease identified three novel presenilin mutations Neurobiol Aging. 2020 86 201.e9 201.e14 10.1016/j.neurobiolaging.2019.01.015 30797548 · DOI
  5. [7]Ettcheto M Cano A Busquets O Manzine P Sánchez-López E Castro-Torres R A metabolic perspective of late onset Alzheimer ’ s disease Pharmacol Res. 2019 145 104255 10.1016/j.phrs.2019.104255 31075308 · DOI
  6. [8]Nation DA Sweeney MD Montagne A Sagare AP D’Orazio LM Maricarmen P Sepehrband F Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction Nat Med 2019 25 270 276 10.1038/s41591-018-0297-y 30643288 PMC6367058 · DOI · Paper page
  7. [9]Nutma E Amor S Peferoen LAN Astrocyte and oligodendrocyte cross-talk in the central nervous system Cells 2020 9 600 10.3390/cells9030600 32138223 PMC7140446 · DOI
  8. [10]Cummings J Zhong K Lee G Ritter A Sabbagh M Alzheimer’ s disease drug development pipeline: 2020 Alzheimer’s Dement 2020 6 e12050 PMC7364858 32695874
  9. [11]Mulvihill JJ Cunnane EM Ross AM Duskey JT Tosi G Grabrucker AM Drug delivery across the blood–brain barrier: recent advances in the use of nanocarriers Nanomedicine (London) 2020 5 2 205 214 10.2217/nnm-2019-0367 31916480 · DOI
  10. [12]Duskey J Belletti D Pederzoli F Vandelli M Forni F Ruozi B Current strategies for the delivery of therapeutic proteins and enzymes to treat brain disorders Int Rev Neurobiol. 2017 137 1 28 10.1016/bs.irn.2017.08.006 29132540 · DOI
  11. [13]Wilczewska AZ Niemirowicz K Markiewicz KH Car H Nanoparticles as drug delivery systems Pharmacol Rep 2012 64 5 1020 1037 10.1016/S1734-1140(12)70901-5 23238461 · DOI · Paper page
  12. [14]Duskey JT Ottonelli I Da Ros F Vilella A Zoli M Kovachka S Novel peptide-conjugated nanomedicines for brain targeting: in vivo evidence Nanomed Nanotechnol Biol Med. 2020 28 102226 10.1016/j.nano.2020.102226 32479916 · DOI
  13. [15]Hippius H The discovery of Alzheimer’s disease Dialogues Clin Neurosci 2003 5 1 101 108 10.31887/DCNS.2003.5.1/hhippius 22034141 PMC3181715 · DOI
  14. [16]Dubois B Feldman HH Cummings JL Dekosky ST Barberger-Gateau P Delacourte A Frisoni G Revising the definition of Alzheimer’s disease: a new lexicon Lancet Neurol. 2010 9 11 1118 1127 10.1016/S1474-4422(10)70223-4 20934914 · DOI · Paper page
  15. [17]Alegret M Muñoz N Roberto N Rentz DM Valero S Gil S A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer’s disease Alzheimers Res Ther 2020 12 1 25 10.1186/s13195-020-00594-6 32178724 PMC7077028 · DOI
  16. [18]Khoury R Ghossoub E Diagnostic biomarkers of Alzheimer’s disease: a state-of-the-art review Biomark Neuropsychiatr 2019 1 100005 10.1016/j.bionps.2019.100005 · DOI
  17. [20]El KN Said N Slassi I Moutawakil E Nadifi S Biomarkers for Alzheimer Disease: classical and novel candidates ’ review Neuroscience 2018 370 181 190 10.1016/j.neuroscience.2017.07.017 28729061 · DOI
  18. [21]Canevelli M Bacigalupo I Gervasi G Lacorte E Massari M Mayer F Methodological Issues in the clinical validation of biomarkers for Alzheimer’ s Disease: the paradigmatic example of CSF Front Aging Neurosci 2019 11 282 10.3389/fnagi.2019.00282 31680936 PMC6812267 · DOI
  19. [22]Rossini PM Iorio RD Vecchio F Anfossi M Babiloni C Bozzali M Early diagnosis of Alzheimer’ s disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts Cli Neurophysiol. 2020 131 6 1287 1310 10.1016/j.clinph.2020.03.003 32302946 · DOI
  20. [23]Blennow K Dubois B Fagan A Lewczuk P de Leon M Hampel H Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease Alzheimer’s Dementia 2015 11 1 58 69 10.1016/j.jalz.2014.02.004 24795085 PMC4386839 · DOI
  21. [25]Trombetta BA Carlyle BC Koenig AM Shaw LM Trojanowski Q Wolk DA The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’ s disease PLoS ONE 2018 13 3 e0193707 10.1371/journal.pone.0193707 29505610 PMC5837100 · DOI
  22. [26]Olsson B Lautner R Andreasson U Öhrfelt A Portelius E Bjerke M CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis Lancet Neurol 2016 15 7 673 684 10.1016/S1474-4422(16)00070-3 27068280 · DOI · Paper page
  23. [27]Park SA Han S Kim CE New fluid biomarkers tracking non-amyloid- β and non-tau pathology in Alzheimer ’ s disease Exp Mol Med 2020 52 556 568 10.1038/s12276-020-0418-9 32284537 PMC7210893 · DOI
  24. [28]Awasthi M Singh S Pandey VP Dwivedi UN Alzheimer â€TM s disease: an overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products J Neurol Sci 2016 361 256 271 10.1016/j.jns.2016.01.008 26810552 · DOI
  25. [29]Milà-Alomà M Suárez-calvet M Molinuevo JL Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer ’ s disease Ther Adv Neurol Disord 2019 12 1 23 10.1177/1756286419888819 PMC6920596 31897088 · DOI
  26. [30]Hrubešová K Fousková M Habartová L Fišar Z Jirák R Search for biomarkers of Alzheimer ‘ s disease: recent insights, current challenges and future prospects Clin Biochem 2019 72 39 51 10.1016/j.clinbiochem.2019.04.002 30953619 · DOI
  27. [31]Lewczuk P Matzen A Blennow K Parnetti L Molinuevo JL Eusebi P Cerebrospinal fluid Aβ42/40 corresponds better than Aβ42 to amyloid PET in Alzheimer’s Disease J Alzheimers Dis 2017 55 2 813 822 10.3233/JAD-160722 27792012 PMC5147502 · DOI
  28. [32]Janelidze S Zetterberg H Mattsson N Palmqvist S Vanderstichele H Lindberg O CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease Ann Clin Transl Neurol 2016 3 3 154 165 10.1002/acn3.274 27042676 PMC4774260 · DOI · Paper page
  29. [33]Pérez-Grijalba V Romero J Pesini P Sarasa L Monleón I San-José I Plasma Aβ42/40 ratio detects early stages of Alzheimer’s disease and correlates with CSF and neuroimaging biomarkers in the AB255 study J Prev Alzheimers Dis 2019 6 1 34 41 30569084
  30. [34]Pérez-Grijalba V Arbizu J Romero J Prieto E Pesini P Sarasa L Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study Alzheimers Res Ther 2019 11 1 96 10.1186/s13195-019-0549-1 31787105 PMC6886187 · DOI
  31. [35]Zetterberg H Blood-based biomarkers for Alzheimer ’ s disease—an update J Neurosci Methods 2019 319 2 6 10.1016/j.jneumeth.2018.10.025 30352211 · DOI
  32. [36]Huynh RA Mohan C Huynh RA Mohan C Alzheimer’s Disease: biomarkers in the genome, blood, and cerebrospinal fluid Front Neurol 2017 8 102 10.3389/fneur.2017.00102 28373857 PMC5357660 · DOI
  33. [37]Schuster J Funke SA Methods for the specific detection and quantitation of amyloid-β oligomers in cerebrospinal fluid J Alzheimers Dis 2016 53 1 53 67 10.3233/JAD-151029 27163804 · DOI
  34. [39]Hampel H, Vassar R, De Strooper B, Hardy J, Willem M, Singh N, et al. The β-Secretase BACE1 in Alzheimer’s Disease. Biological Psychiatry. 2020;In press. PMC7533042 32223911
  35. [41]Ewers M Cheng X Zhong Z Nural HF Walsh C Meindl T Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer’s disease J Alzheimers Dis 2011 25 2 373 381 10.3233/JAD-2011-091153 21460439 · DOI · Paper page
  36. [42]Perneczky R Alexopoulos P Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer’s disease Alzheimers Dement. 2014 10 S425 S429.e1 10.1016/j.jalz.2013.09.006 24239250 PMC4038661 · DOI
  37. [43]Savage MJ Holder DJ Wu G Kaplow J Siuciak JA Potter WZ Soluble BACE-1 activity and sAβPPβ Concentrations in Alzheimer’s Disease and age-matched healthy control cerebrospinal fluid from the Alzheimer’s Disease neuroimaging initiative-1 baseline cohort J Alzheimers Dis 2015 46 2 431 440 10.3233/JAD-142778 25790831 PMC6287641 · DOI
  38. [44]Shen Y Wang H Sun Q Yao H Keegan AP Mullan M Increased plasma BACE1 may predict conversion to Alzheimer’s Disease dementia in individuals with mild cognitive impairment Biol Psychiatry 2018 83 5 447 455 10.1016/j.biopsych.2017.02.007 28359566 PMC5656540 · DOI · Paper page
  39. [45]Grundke-Iqbal I Iqbal K Tung Y Quinlan M Wisniewski H Binder L Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology Proc Natl Acad Sci U S A 1986 83 13 4913 4917 10.1073/pnas.83.13.4913 3088567 PMC323854 · DOI · Paper page
  40. [46]Arendt T Stieler JT Holzer M Tau and tauopathies Brain Res Bull 2016 126 238 292 10.1016/j.brainresbull.2016.08.018 27615390 · DOI · Paper page
  41. [47]Schöll M Maass A Mattsson N Ashton NJ Blennow K Zetterberg H Biomarkers for tau pathology Mol Cell Neurosci 2019 97 18 33 10.1016/j.mcn.2018.12.001 30529601 PMC6584358 · DOI
  42. [48]Wattmo C Blennow K Hansson O Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease BMC Neurol 2020 20 10 10.1186/s12883-019-1591-0 31918679 PMC6951013 · DOI · Paper page
  43. [50]Lleó A Alcolea D Martínez-Lage P Scheltens P Parnetti L Poirier J Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer’s disease continuum in the BIOMARKAPD study Alzheimers Dement 2019 151 6 742 753 10.1016/j.jalz.2019.01.015 30967340 · DOI
  44. [51]Mielke MM Hagen CE Xu J Chai X Vemuri P Lowe VJ Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography Alzheimers Dement 2018 14 8 989 997 10.1016/j.jalz.2018.02.013 29626426 PMC6097897 · DOI · Paper page
  45. [52]Shekhar S Kumar R Rai N Kumar V Singh K Upadhyay AD Estimation of tau and phosphorylated tau181 in serum of Alzheimer’s Disease and mild cognitive impairment patients PLoS ONE 2016 11 7 e0159099 10.1371/journal.pone.0159099 27459603 PMC4961391 · DOI
  46. [53]Yang C-C Chiu M-J Chen T-F Chang H-L Liu B-H Yang S-Y Assay of plasma phosphorylated tau protein (Threonine 181) and total tau protein in early-stage Alzheimer’s Disease J Alzheimers Dis 2018 61 4 1323 1332 10.3233/JAD-170810 29376870 · DOI
  47. [54]Palmqvist S Janelidze S Quiroz YT Zetterberg H Lopera F Stomrud E Discriminative accuracy of plasma phospho-tau217 for Alzheimer Disease vs other neurodegenerative disorders JAMA 2020 324 8 772 781 10.1001/jama.2020.12134 32722745 PMC7388060 · DOI · Paper page
  48. [55]Barthélemy NR Horie K Sato C Bateman RJ Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease J Exp Med 2020 217 11 e20200861 10.1084/jem.20200861 32725127 PMC7596823 · DOI · Paper page
  49. [56]Suárez-Calvet M Karikari T Ashton N Lantero Rodríguez J Milà-Alomà M Gispert J Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected EMBO Mol Med 2020 10 e12921 PMC7721364 33169916
  50. [57]Mattsson-Carlgren N Janelidze S Palmqvist S Cullen N Svenningsson A Strandberg O Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease Brain 2020 17 3234 10.1093/brain/awaa286 PMC7719022 33068398 · DOI · Paper page
  51. [58]Bos I Vos S Verhey F Scheltens P Teunissen C Engelborghs S Sleegers K Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer’s disease spectrum Alzheimers Dement. 2019 15 5 644 654 10.1016/j.jalz.2019.01.004 30853464 · DOI
  52. [59]Skillbäck T Farahmand B Bartlett JW Rosén C Mattsson N Nägga K CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival Neurology 2014 83 21 1945 1953 10.1212/WNL.0000000000001015 25339208 · DOI · Paper page
  53. [60]Mattsson N Cullen NC Andreasson U Zetterberg H Blennow K Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer Disease JAMA Neurol 2019 76 7 791 799 10.1001/jamaneurol.2019.0765 31009028 PMC6583067 · DOI · Paper page
  54. [61]Weston PSJ Poole T O’Connor A Heslegrave A Ryan NS Liang Y Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease Alzheimers Res Ther 2019 11 1 19 10.1186/s13195-019-0472-5 30786919 PMC6383280 · DOI
  55. [62]Raket LL Kühnel L Schmidt E Blennow K Zetterberg H Mattsson-Carlgren N Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer’s disease Alzheimers Dement (Amst) 2020 12 1 e12099 32995466 PMC7507310
  56. [63]Groblewska M Muszyński P Wojtulewska-Supron A Kulczyńska-Przybik A Mroczko B The role of visinin-like protein-1 in the pathophysiology of Alzheimer’s Disease J Alzheimers Dis 2015 47 1 17 32 10.3233/JAD-150060 26402751 · DOI
  57. [64]Zhang H Pin Ng K Therriault J Kang MS Pascoal TA Rosa-Neto P Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease Transl Neurodegener 2018 7 23 10.1186/s40035-018-0127-7 30311914 PMC6161434 · DOI
  58. [65]Regen F Hellmann-Regen J Costantini E Reale M Neuroinflammation and Alzheimer’s Disease: implications for microglial activation Curr Alzheimer Res 2017 14 11 1140 1448 10.2174/1567205014666170203141717 28164764 · DOI
  59. [66]Calsolaro V Edison P Neuroinflammation in Alzheimer ’ s disease: current evidence and future directions Alzheimer’s Dementia 2016 12 6 719 732 10.1016/j.jalz.2016.02.010 27179961 · DOI · Paper page
  60. [67]Mizuno T The biphasic role of microglia in Alzheimer’ s disease Int J Alzheimer’s Dis 2012 2012 737846 1 9 PMC3357927 22655214
  61. [69]Sjögren M Blomberg M Jonsson M Wahlund L Edman A Lind K Neurofilament protein in cerebrospinal fluid: a marker of white matter changes J Neurosci Res 2001 66 3 510 516 10.1002/jnr.1242 11746370 · DOI · Paper page
  62. [70]Parbo P Madsen LS Ismail R Zetterberg H Blennow K Eskildsen SF Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer ’ s disease Alzheimer’s Res Therapy 2020 12 3 1 7 PMC6941285 31898549
  63. [71]Khalil M Pirpamer L Hofer E Voortman MM Barro C Leppert D Serum neurofilament light levels in normal aging and their association with morphologic brain changes Nat Commun 2020 11 812 10.1038/s41467-020-14612-6 32041951 PMC7010701 · DOI · Paper page
  64. [72]Baldacci F Lista S Cavedo E Bonuccelli U Hampel H Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases Expert Rev Proteomics 2017 14 4 285 299 10.1080/14789450.2017.1304217 28281838 · DOI · Paper page
  65. [73]Mendsaikhan A Tooyama I Walker DG Microglial progranulin: involvement in Alzheimer’s Disease and neurodegenerative diseases Cells 2019 8 3 230 10.3390/cells8030230 30862089 PMC6468562 · DOI · Paper page
  66. [74]Ahmed Z Mackenzie IR Hutton ML Dickson DW Progranulin in frontotemporal lobar degeneration and neuroinflammation J Neuroinflammation 2007 4 7 1 13 17291356 PMC1805428
  67. [76]Wilke C Gillardon F Deuschle C Dubois E Hobert MA vom Hagen MJ Serum levels of progranulin do not reflect cerebrospinal fluid levels in neurodegenerative disease Curr Alzheimer Res. 2016 13 6 654 662 10.2174/1567205013666160314151247 26971930 · DOI
  68. [77]Zhou Y Ulland TK Colonna M TREM2-dependent effects on microglia in Alzheimer’s Disease Front Aging Neurosci 2018 10 202 10.3389/fnagi.2018.00202 30038567 PMC6046445 · DOI
  69. [78]Jonsson T Stefansson H Steinberg S Jonsdottir I Jonsson PV Snaedal J Variant of TREM2 associated with the risk of Alzheimer’s disease N Engl J Med 2013 368 2 107 116 10.1056/NEJMoa1211103 23150908 PMC3677583 · DOI · Paper page
  70. [79]Chen S Peng J Sherchan P Ma Y Xiang S Yan F TREM2 activation attenuates neuroinflammation and neuronal apoptosis via PI3K/Akt pathway after intracerebral hemorrhage in mice J Neuroinflammation 2020 17 168 10.1186/s12974-020-01853-x 32466767 PMC7257134 · DOI
  71. [80]Zhong L Xu Y Zhuo R Wang T Wang K Huang R Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model Nat Commun 2019 10 1 1365 10.1038/s41467-019-09118-9 30911003 PMC6433910 · DOI · Paper page
  72. [82]Lista S Hampel H Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer’s disease Expert Rev Neurother 2017 17 1 47 57 10.1080/14737175.2016.1204234 27332958 · DOI
  73. [83]Overk CR Masliah E Pathogenesis of synaptic degeneration in Alzheimer’s disease and Lewy Body disease Biochem Pharmacol 2014 88 4 508 516 10.1016/j.bcp.2014.01.015 24462903 PMC3973539 · DOI · Paper page
  74. [84]Cheetham JE Martzen MR Kazee AM Coleman PD Gap-43 message levels in anterior cerebellum in Alzheimer’s disease Brain Res Mol Brain Res 1996 36 1 145 151 10.1016/0169-328X(95)00257-S 9011750 · DOI
  75. [85]Sandelius Å Portelius E Källén Å Zetterberg H Rot U Olsson B Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology Alzheimers Dement 2019 15 1 55 64 10.1016/j.jalz.2018.08.006 30321501 PMC6333489 · DOI
  76. [86]Zhang H Therriault J Kang MS Pin Ng K Pascoal TA Rosa-Neto P Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease Alzheimers Res Ther 2018 10 1 80 10.1186/s13195-018-0407-6 30115118 PMC6097333 · DOI
  77. [87]Wang S Zhang J Pan T APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer’s disease Neurosci Lett 2018 685 109 113 10.1016/j.neulet.2018.08.029 30144541 · DOI
  78. [88]Agliardi C Guerini FR Zanzottera M Bianchi A Nemni R Clerici M SNAP-25 in serum is carried by exosomes of neuronal origin and is a potential biomarker of Alzheimer’s Disease Mol Neurobiol 2019 56 8 5792 5798 10.1007/s12035-019-1501-x 30680692 · DOI
  79. [89]Davidsson P Jahn R Bergquist J Ekman R Blennow K Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease? Mol Chem Neuropathol 1996 27 2 195 210 10.1007/BF02815094 8962603 · DOI
  80. [91]Tarawneh R D’Angelo G Crimmins D Herries E Griest T Fagan AM Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer Disease JAMA Neurol 2016 73 5 561 571 10.1001/jamaneurol.2016.0086 27018940 PMC4861689 · DOI
  81. [92]Dhiman K Blennow K Zetterberg H Martins RN Gupta VB Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis Cell Mol Life Sci 2019 76 10 1833 1863 10.1007/s00018-019-03040-5 30770953 PMC11105672 · DOI
  82. [93]Kirsebom B-E Nordengen K Selnes P Waterloo K Bøen Torsetnes S Gísladóttir B Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer’s disease Alzheimers Dement (N Y) 2018 4 617 627 10.1016/j.trci.2018.10.003 30519627 PMC6260221 · DOI
  83. [94]Di Marco LY Venneri A Farkas E Evans PC Marzo A Frangi AF Vascular dysfunction in the pathogenesis of Alzheimer’s disease–a review of endothelium-mediated mechanisms and ensuing vicious circles Neurobiol Dis. 2015 82 593 606 10.1016/j.nbd.2015.08.014 26311408 · DOI
  84. [95]Tibbling G Link H Ohman S Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values Scand J Clin Lab Invest. 1997 37 5 385 390 10.3109/00365517709091496 337459 · DOI
  85. [97]Belloy ME Napolioni V Greicius MD A quarter century of APOE and Alzheimer’s Disease: progress to date and the path forward Neuron 2019 101 5 820 838 10.1016/j.neuron.2019.01.056 30844401 PMC6407643 · DOI · Paper page
  86. [99]Heywood WE Galimberti D Bliss E Sirka E Paterson RW Magdalinou NK Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay Mol Neurodegener 2015 10 64 10.1186/s13024-015-0059-y 26627638 PMC4666172 · DOI
  87. [101]Wang S Mims PN Roman RJ Fan F Is beta-amyloid accumulation a cause or consequence of Alzheimer’s Disease? J Alzheimers Parkinsonism Dement 2016 1 2 1 8 PMC5555607 28815226
  88. [102]Ballard C Gauthier S Corbett A Brayne C Aarsland D Jones E Alzheimer ’ s disease Lancet 2011 377 9770 1019 1031 10.1016/S0140-6736(10)61349-9 21371747 · DOI · Paper page
  89. [104]Smith A Giunta B Bickford PC Fountain M Tan J Shytle RD Nanolipidic particles improve the bioavailability and α -secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer’ s disease Int J Pharm 2010 389 1–2 207 212 10.1016/j.ijpharm.2010.01.012 20083179 PMC5831366 · DOI · Paper page
  90. [105]de la Torre R. Prevention of cognitive decline in ApoE4 Carriers with subjective cognitive decline after EGCG and a multimodal intervention ((PENSA)). ClinicalTrials.gov. 2021. https://clinicaltrials.gov/ct2/show/NCT03978052. PMC8012239 33816762
  91. [106]Marcade M Bourdin J Loiseau N Peillon H Rayer A Drouin D Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing J Neurochemistry 2008 106 392 404 10.1111/j.1471-4159.2008.05396.x 18397369 · DOI
  92. [107]Li Z New APOE-related therapeutic options for Alzheimer ’ s disease AIP Conf Proc 2019 2058 20002 10.1063/1.5085515 · DOI
  93. [109]Kim DE Priefer R Therapeutic potential of direct clearance of the amyloid- β in Alzheimer’s Disease Brain Sci 2020 10 93 10.3390/brainsci10020093 32050618 PMC7071829 · DOI
  94. [110]Sevigny J Chiao P Bussière T Weinreb PH Williams L Maier M Addendum: the antibody aducanumab reduces Aβ plaques in Alzheimer’s disease Nature 2017 546 7659 564 10.1038/nature22809 28640269 · DOI · Paper page
  95. [112]Boada M Ramos-Fernández E Guivernau B Muñoz F Costa M Ortiz A Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study Neurologia 2016 31 7 473 481 10.1016/j.nrl.2014.02.003 25023458 · DOI
  96. [113]Boada M López O Núñez L Szczepiorkowski ZM Torres M Grifols C Plasma exchange for Alzheimer’s disease Management by Albumin Replacement (AMBAR) trial: study design and progress Alzheimers Dement (N Y) 2019 5 61 69 10.1016/j.trci.2019.01.001 30859122 PMC6395854 · DOI · Paper page
  97. [114]Boada M López OL Olazarán J Núñez L Pfeffer M Paricio M A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: primary results of the AMBAR Study Alzheimer’s Dement 2020 16 1412 1425 10.1002/alz.12137 32715623 PMC7984263 · DOI · Paper page
  98. [115]Chong FP Ng KY Koh RY Moi CS Tau proteins and tauopathies in Alzheimer’s Disease Cell Mol Neurobiol Vol 2018 38 965 980 10.1007/s10571-017-0574-1 PMC11481908 29299792 · DOI
  99. [116]Rajmohan R Reddy PH Amyloid beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer’s Disease neurons J Alzheimers Dis 2018 57 4 975 999 10.3233/JAD-160612 PMC5793225 27567878 · DOI
  100. [117]Avila J León-Espinosa G García E García-Escudero V Hernández F DeFelipe J Tau phosphorylation by GSK3 in different conditions Int J Alzheimer’s Dis 2012 2012 578373 22675648 PMC3362846
  101. [118]Hampel H Mesulam M Cuello AC Farlow MR Giacobini E Grossberg GT The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease Brain 2018 141 1917 1933 10.1093/brain/awy132 29850777 PMC6022632 · DOI · Paper page
  102. [119]Pittel Z Heldman E Barg J Haring R Fisher A Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum Brain Res 1996 742 1–2 299 304 10.1016/S0006-8993(96)01031-1 9117408 · DOI
  103. [120]Gandía L Álvarez R De Pascual R Rojo J Tapia L Anticholinesterases in the treatment of Alzheimer’s disease Rev Neurol 2006 42 8 471 477 16625509
  104. [121]López-Álvarez J Sevilla-Llewellyn-Jones J Agüera-Ortiz L Anticholinergic drugs in geriatric psychopharmacology Front Neurosci 2019 13 1309 10.3389/fnins.2019.01309 31866817 PMC6908498 · DOI
  105. [122]Suzuki M Nelson A Eickstaedt J Wallace K Wright L Svendsen CN Glutamate enhances proliferation and neurogenesis in human neural progenitor cell cultures derived from the fetal cortex Eur J Neurosci 2006 24 3 645 653 10.1111/j.1460-9568.2006.04957.x 16848797 · DOI
  106. [123]Danysz W Parsons C Alzheimer’s disease, β-amyloid, glutamate, NMDA receptors and memantine-searching for the connections Br J Pharmacol 2012 167 2 324 352 10.1111/j.1476-5381.2012.02057.x 22646481 PMC3481041 · DOI · Paper page
  107. [124]Huang WJ Zhang X Chen W Role of oxidative stress in Alzheimer’s disease Biomed Rep 2016 4 519 522 10.3892/br.2016.630 27123241 PMC4840676 · DOI · Paper page
  108. [125]Nunomura A Perry G Aliev G Hirai K Takeda A Balraj EK Oxidative damage is the earliest event in Alzheimer disease J Neuropathol Exp Neurol 2009 60 8 759 767 10.1093/jnen/60.8.759 11487050 · DOI · Paper page
  109. [126]Essa MM, Akbar M, Gilles G. The benefits of natural products for neurodegenerative diseases. 2016. pp. 107–123.
  110. [127]Hemonnot A Hua J Ulmann L Hirbec H Microglia in Alzheimer Disease: well-known targets and new opportunities Front Aging Neurosci 2019 11 1 20 10.3389/fnagi.2019.00233 31543810 PMC6730262 · DOI · Paper page
  111. [128]Arranz AM De SB The role of astroglia in Alzheimer’s disease: pathophysiology and clinical implications Lancet Neurol 2019 18 4 406 414 10.1016/S1474-4422(18)30490-3 30795987 · DOI
  112. [129]Bronzuoli M Iacomino A Steardo L Scuderi C Targeting neuroinflammation in Alzheimer’s disease J Inflamm Res 2016 9 199 208 10.2147/JIR.S86958 27843334 PMC5098782 · DOI
  113. [130]Ali MM Ghouri RG Ans AH Akbar A Toheed A Recommendations for anti-inflammatory treatments in Alzheimer’s Disease: a comprehensive review of the literature Cureus 2019 11 5 e4620 31312547 PMC6615583
  114. [131]Onyango IG Dennis J Khan SM Biotechnology G St BF Mitochondrial dysfunction in Alzheimer’s Disease and the rationale for bioenergetics based therapies Aging Dis 2016 7 2 201 214 10.14336/AD.2015.1007 27114851 PMC4809610 · DOI · Paper page
  115. [132]Anand R Gill K Mahdi A Therapeutics of Alzheimer’s disease: past, present and future Neuropharmacology 2014 76 27 50 10.1016/j.neuropharm.2013.07.004 23891641 · DOI
  116. [133]Maczurek A Hager K Kenklies M Sharman M Martins R Engel J Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer’s disease Adv Drug Deliv Rev 2008 60 1463 1470 10.1016/j.addr.2008.04.015 18655815 · DOI
  117. [134]Bachurin S Bukatina E Lermontova N Tkachenko S Afanasiev A Grigoriev V Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer Ann N Y Acad Sci 2001 939 425 435 10.1111/j.1749-6632.2001.tb03654.x 11462798 · DOI
  118. [135]Woong Lim J Lee J Pae N Mitochondrial dysfunction and Alzheimer’s disease: prospects for therapeutic intervention BMB Rep 2020 53 1 47 55 10.5483/BMBRep.2020.53.1.279 31818365 PMC6999825 · DOI
  119. [136]Craft S The role of metabolic disorders in Alzheimer’s Disease and vascular dementia: two roads converged? Arch Neurol 2009 66 3 300 305 10.1001/archneurol.2009.27 19273747 PMC2717716 · DOI · Paper page
  120. [137]Chu C-S Tseng P-T Stubbs B Chen T-Y Tang C-H Li D-J Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis Sci Rep 2018 8 5804 10.1038/s41598-018-24248-8 29643479 PMC5895617 · DOI
  121. [138]Bendlin BB Antidiabetic therapies and Alzheimer disease Dialogues Clin Neurosci 2019 21 1 83 91 10.31887/DCNS.2019.21.1/bablendin 31607783 PMC6780353 · DOI
  122. [139]Yun YH Lee BK Park K Lafayette W Controlled drug delivery: historical perspective for the next generation J Control Release 2015 219 2 7 10.1016/j.jconrel.2015.10.005 26456749 PMC4656096 · DOI
  123. [140]Yun Y Lee B Park K Controlled drug delivery systems: the next 30 years Front Chem Sci Eng 2014 8 3 276 279 10.1007/s11705-014-1426-x · DOI
  124. [141]Bassyouni F Elhalwany N Advances and new technologies applied in controlled drug delivery system Res Chem Intermed 2015 41 2165 2200 10.1007/s11164-013-1338-2 · DOI
  125. [142]Benoit DSW, Overby CT, Jr KRS, Ackun-farmmer MA. 2.5.12 - Drug Delivery Systems. Fourth Edi. Biomaterials Science. Elsevier Inc.; 2020. pp. 1237–1259.e3. 10.1016/B978-0-12-816137-1.00079-9 · DOI
  126. [144]Kouyoumdjian H Zhu DC El-Dakdouki MH Lorenz K Chen J Li W Glyconanoparticle aided detection of β-Amyloid by Magnetic resonance imaging and attenuation of β-Amyloid Induced Cytotoxicity ACS Chem Neurosci 2013 4 4 575 584 10.1021/cn3002015 23590250 PMC3629742 · DOI
  127. [145]Viola KL Sbarboro J Sureka R De M Bicca MA Wang J Towards non-invasive diagnostic imaging of early-stage Alzheimer’s disease Nat Nanotechnol 2015 10 1 91 98 10.1038/nnano.2014.254 25531084 PMC4300856 · DOI
  128. [146]Tanifum EA Ghaghada K Vollert C Head E Eriksen JL Annapragada A A novel liposomal nanoparticle for the imaging of amyloid plaque by magnetic resonance imaging J Alzheimers Dis 2016 52 2 731 745 10.3233/JAD-151124 27031484 PMC4931553 · DOI
  129. [147]Gavhanea YN Yadav AV Loss of orally administered drugs in GI tract Saudi Pharm J 2012 20 4 331 344 10.1016/j.jsps.2012.03.005 23960808 PMC3744959 · DOI
  130. [148]Hoosain FG Choonara YE Tomar LK Kumar P Tyagi C du Toit LC Bypassing P-glycoprotein drug efflux mechanisms: possible applications in pharmacoresistant schizophrenia therapy Biomed Res Int 2015 2015 484963 10.1155/2015/484963 26491671 PMC4600488 · DOI
  131. [149]Lennernäs H Abrahamsson B The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension J Pharm Pharmacol 2005 57 3 273 285 10.1211/0022357055263 15807982 · DOI
  132. [150]Cano A Sánchez-López E Ettcheto M López-Machado A Espina M Souto EB Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases Nanomedicine (London) 2020 15 12 1239 1261 10.2217/nnm-2019-0443 32370600 · DOI · Paper page
  133. [151]Alvarez-Erviti L Seow Y Yin H Betts C Lakhal S Wood M Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat Biotechnol 2011 29 341 345 10.1038/nbt.1807 21423189 · DOI · Paper page
  134. [152]Tajes M Ramos-fernández E Weng-jiang X Bosch-morató M Guivernau B Eraso-pichot A The blood-brain barrier: structure, function and therapeutic approaches to cross it Mol Membr Biol 2014 31 5 152 167 10.3109/09687688.2014.937468 25046533 · DOI · Paper page
  135. [153]Gordillo-galeano A Mora-huertas CE Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release Eur J Pharm Biopharm 2018 133 285 308 10.1016/j.ejpb.2018.10.017 30463794 · DOI
  136. [154]Cano A Espina M García M Recent advances on anti-tumor agents-loaded polymeric and lipid based nano-carriers for the treatment of brain cancer Curr Pharm Des 2020 26 12 1316 1330 10.2174/1381612826666200116142922 31951159 · DOI
  137. [155]Campani V Giarra S De RG Lipid-based core-shell nanoparticles: evolution and potentialities in drug delivery OpenNano 2018 3 5 17 10.1016/j.onano.2017.12.001 · DOI
  138. [156]Kraft J Freeling J Wang Z Ho R Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems J Pharm Sci 2014 103 1 29 52 10.1002/jps.23773 24338748 PMC4074410 · DOI
  139. [157]Almuhayawi MS Ramadan WS Harakeh S Al SK Bharali DJ Mousa SA The potential role of pomegranate and its nano-formulations on cerebral neurons in aluminum chloride induced Alzheimer rat model Saudi J Biol Sci 2020 27 7 1710 1716 10.1016/j.sjbs.2020.04.045 32565686 PMC7296487 · DOI
  140. [158]Giacomeli R Cristina J Bem R Peterini S Ricardo C Elisa S Neuroprotective effects of curcumin lipid-core nanocapsules in a model Alzheimer’s disease induced by β-amyloid 1–42 peptide in aged female mice Brain Res 2019 1721 146325 10.1016/j.brainres.2019.146325 31325424 · DOI
  141. [159]Gupta SC Patchva S Aggarwal BB Therapeutic roles of curcumin: lessons learned from clinical trials AAPS J 2013 15 1 195 218 10.1208/s12248-012-9432-8 23143785 PMC3535097 · DOI
  142. [160]Willson J Transferrin’ across the blood–brain barrier Nat Rev Drug Discov 2020 19 444 10.1038/d41573-020-00102-3 32504057 · DOI
  143. [161]Pinheiro RGR Granja A Loureiro JA Pereira MC Pinheiro M Neves AR Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer`s disease Eur J Pharm Sci 2020 148 105314 10.1016/j.ejps.2020.105314 32200044 · DOI
  144. [162]Kamatou GPP Viljoen AM A review of the application and pharmacological properties of α-Bisabolol and α-Bisabolol-rich oils JAOCS 2010 87 1 1 7 10.1007/s11746-009-1483-3 · DOI · Paper page
  145. [163]Sathya S Shanmuganathan B Manirathinam G Ruckmani K Pandima K α -Bisabolol loaded solid lipid nanoparticles attenuates A β aggregation and protects Neuro-2a cells from A β induced neurotoxicity J Mol Liq 2018 264 431 441 10.1016/j.molliq.2018.05.075 · DOI
  146. [164]Sathya S Shanmuganathan B Devi KP Deciphering the anti-apoptotic potential of α -bisabolol loaded solid lipid nanoparticles against A β induced neurotoxicity in Neuro-2a cells Colloids Surf B 2020 190 110948 10.1016/j.colsurfb.2020.110948 32160583 · DOI
  147. [165]Dara T Vatanara A Sharifzadeh M Khani S Improvement of memory deficits in the rat model of Alzheimer`s disease by erythropoietin-loaded solid lipid nanoparticles Neurobiol Learn Mem 2019 166 107082 10.1016/j.nlm.2019.107082 31493483 · DOI
  148. [166]Punnonen J Miller JL Collier TJ Spencer JR Agonists of the tissue-protective erythropoietin receptor in the treatment of Parkinson’s disease Curr Top Med Chem 2015 15 10 955 969 10.2174/156802661510150328224527 25832721 · DOI
  149. [167]Cevik B Solmaz V Yigitturk G Cavusoğlu T Gonul P Erbas O Neuroprotective effects of erythropoietin on Alzheimer’s dementia model in rats Adv Clin Exp Med 2017 26 1 23 29 10.17219/acem/61044 28397428 · DOI
  150. [168]Kumari A Yadav SK Yadav SC Biodegradable polymeric nanoparticles based drug delivery systems Colloids Surf B 2010 75 1 18 10.1016/j.colsurfb.2009.09.001 19782542 · DOI
  151. [169]Reis CP Neufeld RJ Nanoencapsulation. I. Methods for preparation of drug-loaded polymeric nanoparticles Nanomed Nanotechnol Biol Med. 2006 2 8 21 10.1016/j.nano.2005.12.003 17292111 · DOI
  152. [170]El-say KM El-sawy HS Polymeric nanoparticles: Promising platform for drug delivery Int J Pharm 2017 528 1–2 675 691 10.1016/j.ijpharm.2017.06.052 28629982 · DOI
  153. [171]Liu S Qiao S Li L Qi G Lin Y Surface charge-conversion polymeric nanoparticles for photodynamic treatment of urinary tract bacterial infections Nanotechnology 2015 26 495602 10.1088/0957-4484/26/49/495602 26572164 · DOI
  154. [172]Nagavarma BVN Yadav HKS Ayaz A Vasudha LS Shivakumar HG Different techniques for preparation of polymeric nanoparticles-a review Asian J Pharm Clin Res 2012 5 3 16 23
  155. [173]Wischke C Schwendeman SP Principles of encapsulating hydrophobic drugs in PLA / PLGA microparticles Int J Pharm 2008 364 298 327 10.1016/j.ijpharm.2008.04.042 18621492 · DOI
  156. [174]Dhas N Mehta T Cationic biopolymer functionalized nanoparticles encapsulating lutein to attenuate oxidative stress in effective treatment of Alzheimer’s disease: a non-invasive approach Int J Pharm 2020 586 119553 10.1016/j.ijpharm.2020.119553 32561306 · DOI
  157. [175]Jia Y-P Sun L Yu H-S Liang L-P Li W Ding H The Pharmacological effects of lutein and zeaxanthin on visual disorders and cognition diseases Molecules 2017 22 4 610 10.3390/molecules22040610 28425969 PMC6154331 · DOI
  158. [176]Sathya S Shanmuganathan B Balasubramaniam B Balamurugan K Devi KP Phytol loaded PLGA nanoparticles regulate the expression of Alzheimer’s related genes and neuronal apoptosis against amyloid- β induced toxicity in Neuro-2a cells and transgenic Caenorhabditis elegans Food Chem Toxicol 2020 136 110962 10.1016/j.fct.2019.110962 31734340 · DOI
  159. [177]Islam MT Ali ES Uddin SJ Shaw S Islam MA Ahmed MI Phytol: a review of biomedical activities Food Chem Toxicol 2019 121 82 94 10.1016/j.fct.2018.08.032 30130593 · DOI · Paper page
  160. [179]Chowdhury A Sarkar J Chakraborti T Pramanik PK Chakraborti S Protective role of epigallocatechin-3-gallate in health and disease: a perspective Biomed Pharmacother 2016 78 50 59 10.1016/j.biopha.2015.12.013 26898424 · DOI · Paper page
  161. [180]Ahlschwede KM Curran GL Rosenberg JT Grant SC Sarkar G Jenkins RB Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer’ s disease brain Nanomed Nanotechnol Biol Med. 2019 16 258 266 10.1016/j.nano.2018.09.010 30300748 · DOI
  162. [181]Liu C Lu D You X Shi G Deng J Carbon dots sensitized lanthanide infinite coordination polymer nanoparticles: towards ratiometric fluorescent sensing of cerebrospinal Aβ monomer as a biomarker for Alzheimer’s disease Anal Chim Acta 2020 1105 147 154 10.1016/j.aca.2020.01.021 32138913 · DOI
  163. [182]Jeon SG Cha M Kim J Hwang TW Kim KA Kim TH Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer’ s disease-related pathology in 5XFAD mice Nanomed Nanotechnol Biol Med. 2019 17 297 307 10.1016/j.nano.2019.02.004 30794963 · DOI
  164. [183]Zhang J Sokal I Peskind ER Quinn JF Jankovic J Kenney C CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases Am J Clin Pathol 2008 129 4 526 529 10.1309/W01Y0B808EMEH12L 18343778 PMC2688655 · DOI
  165. [184]Bishnoi RJ Palmer RF Royall DR Vitamin D binding protein as a serum biomarker of Alzheimer’s disease J Alzheimers Dis 2015 43 1 37 45 10.3233/JAD-140042 25079796 · DOI
  166. [185]Guo Q Xu S Yang P Wang P Lu S Sheng D A dual-ligand fusion peptide improves the brain-neuron targeting of nanocarriers in Alzheimer’s disease mice J Control Release 2020 320 347 362 10.1016/j.jconrel.2020.01.039 31978446 · DOI
  167. [186]Klebowski B Depciuch J Parlinska-Wojtan M Baran J Applications of noble metal-based nanoparticles in medicine Int J Mol Sci 2018 19 4031 10.3390/ijms19124031 30551592 PMC6320918 · DOI
  168. [187]Sánchez-lópez E Gomes D Esteruelas G Bonilla L Lopez-machado AL Galindo R Metal-based nanoparticles as antimicrobial agents: an overview Nanomaterials 2020 10 2 292 10.3390/nano10020292 32050443 PMC7075170 · DOI · Paper page
  169. [188]Khan ZUH Khan A Chen Y Shah NS Muhammad N Khan AU Biomedical applications of green synthesized Nobel metal nanoparticles J Photochem Photobiol B 2017 173 150 164 10.1016/j.jphotobiol.2017.05.034 28582711 · DOI
  170. [189]Govindrao P Ghule NW Haque A Kalaskar MG Metal nanoparticles synthesis: an overview on methods of preparation, advantages and disadvantages, and applications J Drug Deliv Sci Technol 2019 53 101174 10.1016/j.jddst.2019.101174 · DOI
  171. [190]Rana A, Yadav K, Jagadevan S. A comprehensive review on green synthesis of nature-inspired metal nanoparticles: Mechanism, application and toxicity. J Cleaner Prod. 2020;122880.
  172. [191]Wu K Su D Liu J Saha R Wang J-P Magnetic nanoparticles in nanomedicine: a review of recent advances Nanotechnology 2019 30 50 502003 10.1088/1361-6528/ab4241 31491782 · DOI
  173. [192]da Silva W Brett CMA Novel biosensor for acetylcholine based on acetylcholinesterase / poly (neutral red)—deep eutectic solvent / Fe2O3 nanoparticle modified electrode J Electroanal Chem. 2020 872 114050 10.1016/j.jelechem.2020.114050 · DOI
  174. [193]Xing Y Feng X-Z Zhang L Hou J Han G-C Chen Z A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles Int J Nanomed 2017 12 3171 3179 10.2147/IJN.S132776 PMC5402878 28458538 · DOI
  175. [194]Liu Y Zhou H Yin T Gong Y Yuan G Chen L Quercetin-modified gold-palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer’ s disease J Colloid Interf Sci 2019 552 388 400 10.1016/j.jcis.2019.05.066 31151017 · DOI
  176. [195]Gao F Zhao J Liu P Ji D Zhang L Zhang M Preparation and in vitro evaluation of multi-target-directed selenium- chondroitin sulfate nanoparticles in protecting against the Alzheimer ’ s disease Int J Biol Macromol 2020 142 265 276 10.1016/j.ijbiomac.2019.09.098 31593732 · DOI
  177. [196]Kwok JCF Warren P Fawcett JW Chondroitin sulfate: a key molecule in the brain matrix Int J Biochem Cell Biol 2012 44 4 582 586 10.1016/j.biocel.2012.01.004 22265655 · DOI
  178. [197]Solovyev ND Importance of selenium and selenoprotein for brain function: from antioxidant protection to neuronal signalling J Inorg Biochem 2015 153 1 12 10.1016/j.jinorgbio.2015.09.003 26398431 · DOI
  179. [198]Sonawane SK Ahmad A Chinnathambi S Protein-capped metal nanoparticles inhibit tau aggregation in Alzheimer’s Disease ACS Omega 2019 4 12833 12840 10.1021/acsomega.9b01411 31460408 PMC6682074 · DOI
  180. [199]Yang L Yin T Liu Y Sun J Zhou Y Liu J Gold nanoparticle-capped mesoporous silica-based H2O2 -responsive controlled release system for Alzheimer`s disease treatment Acta Biomater 2016 46 177 190 10.1016/j.actbio.2016.09.010 27619837 · DOI
  181. [200]Zhang L Zhao P Yue C Jin Z Liu Q Du X Sustained release of bioactive hydrogen by Pd hydride nanoparticles overcomes Alzheimer’s disease Biomaterials 2019 197 393 404 10.1016/j.biomaterials.2019.01.037 30703744 · DOI
  182. [201]Cai J Dao P Chen H Yan L Liang Y Zhang W Ultrasmall superparamagnetic iron oxide nanoparticles-bound NIR dyes: novel theranostic agents for Alzheimer’s disease Dyes Pigm 2020 173 107968 10.1016/j.dyepig.2019.107968 · DOI
  183. [202]Wahle T Sofranko A Dekkers S Miller MR Heusinkveld HJ Albrecht C Evaluation of neurological effects of cerium dioxide nanoparticles doped with different amounts of zirconium following inhalation exposure in mouse models of Alzheimer ’s and vascular disease Neurochem Int 2020 138 104755 10.1016/j.neuint.2020.104755 32422323 PMC7397505 · DOI

Cited by

Sorted by citations

Authors
Cano, A., Turowski, P., Ettcheto, M., Duskey, J. T., Tosi, G., Sánchez-López, E., García, M. L., Camins, A., Souto, E. B., Ruiz, A., Marquié, M., & Boada, M.
Affiliations
  • Universitat Internacional de Catalunya (ES)
  • University College London (GB)
  • Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
  • University of Modena and Reggio Emilia (IT)
  • University of Coimbra (PT)
Corresponding author
Cano, Amanda
ORCID
Venue
Journal of Nanobiotechnology
Publisher
Springer Science and Business Media LLC
Published
2021-04-29
Volume
19
Issue
1
Pages
122-122
ISSN
1477-3155 (ISSN-L)
DOI
10.1186/s12951-021-00864-x
PMC
PMC8086346
OpenAlex
W3159530706
Cited by
122
References
16
Citations by year
2026: 10 · 2025: 26 · 2024: 28 · 2023: 30 · 2022: 22 · 2021: 5 · 2014: 1
FWCI
2.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Nanobiotechnology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Estudo Geral (Universidad de Coimbra) (submittedVersion, cc-by)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
Funders
  • Instituto de Salud Carlos III (PI17/01474, PI19/00335)
  • Ministerio de Economía y Competitividad (SAF2017-84283-R)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
Alzheimer's disease, biomarkers, nanomedicine, early diagnosis, disease progression monitoring, nanodevices, nanoparticles, brain drug delivery, neurofilament light chain, tau phosphorylation, YKL-40, BACE inhibitors, polymeric nanoparticles, lipid nanoparticles, metal-based nanoparticles, Alzheimer's disease therapeutics
MeSH terms
Aging, Alzheimer Disease, Animals, Brain, Humans, Biomarkers, Amyloid beta-Peptides, Drug Delivery Systems, Oxidative Stress, Nanomedicine, Metal Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review